30/05/1402
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein
Objective(s): SLC39A6 (solute carrier family 39) or LIV-1, is a
zinc-transporter protein associated with estrogen-positive breast cancer
and its metastatic spread. Significantly there is a direct relation
between high zinc intake and unregulated cell proliferation and cancers.
Blocking SLC39A6 protein may result in reduced metastasis and
proliferation in many malignant tumors. This study aimed to develop an
anti-SLC39A6 nanobody that is able to detect and block the SLC39A6
protein on the surface of cancerous cells.
Materials and Methods:
The recombinant SLC39A6 was expressed and used for camel immunization.
The VHH library was constructed and screened for SLC39A6-specific
nanobody. Then, the strength of nanobody in SLC39A6 detection was
evaluated by Western blotting and flow cytometry.
Results: We showed
the ability of SLC39A6 specific Nanobody (C3) to detect SLC39A6 by
Western blotting and flow cytometry. Furthermore, the C3 nanobody
potently inhibits cell proliferation in MTT assay.
Conclusion: These
data show the potential of SLC39A6-specific nanobody for the blockade of
zinc transporter protein and provide a basis for the development of
novel cancer therapeutics.